Juncture Wealth Strategies LLC Decreases Stake in Vericel Co. (NASDAQ:VCEL)

Juncture Wealth Strategies LLC reduced its position in shares of Vericel Co. (NASDAQ:VCEL) by 11.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 10,353 shares of the biotechnology company’s stock after selling 1,290 shares during the period. Juncture Wealth Strategies LLC’s holdings in Vericel were worth $568,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Envestnet Asset Management Inc. raised its holdings in Vericel by 4.5% in the 2nd quarter. Envestnet Asset Management Inc. now owns 158,205 shares of the biotechnology company’s stock worth $7,258,000 after purchasing an additional 6,873 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Vericel by 3.1% during the second quarter. Dimensional Fund Advisors LP now owns 661,018 shares of the biotechnology company’s stock valued at $30,329,000 after buying an additional 19,803 shares during the period. Sei Investments Co. grew its position in shares of Vericel by 25.9% in the 2nd quarter. Sei Investments Co. now owns 62,139 shares of the biotechnology company’s stock worth $2,851,000 after buying an additional 12,799 shares during the period. Squarepoint Ops LLC bought a new position in shares of Vericel in the 2nd quarter worth about $513,000. Finally, The Manufacturers Life Insurance Company grew its holdings in Vericel by 5.4% in the second quarter. The Manufacturers Life Insurance Company now owns 26,472 shares of the biotechnology company’s stock worth $1,215,000 after purchasing an additional 1,355 shares during the period.

Vericel Trading Up 0.0 %

NASDAQ VCEL opened at $57.43 on Friday. The stock’s 50 day moving average is $57.40 and its 200 day moving average is $50.47. Vericel Co. has a 12 month low of $39.12 and a 12 month high of $61.49. The stock has a market cap of $2.83 billion, a PE ratio of 957.33 and a beta of 1.72.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.03. The company had revenue of $57.91 million for the quarter, compared to analysts’ expectations of $55.32 million. Vericel had a net margin of 1.56% and a return on equity of 1.48%. On average, analysts forecast that Vericel Co. will post 0.12 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on VCEL. Canaccord Genuity Group reissued a “buy” rating and issued a $60.00 target price on shares of Vericel in a research note on Tuesday, November 19th. Stephens reiterated an “overweight” rating and set a $65.00 target price on shares of Vericel in a research note on Wednesday, January 15th. StockNews.com upgraded Vericel from a “sell” rating to a “hold” rating in a research note on Tuesday, December 24th. BTIG Research upped their target price on shares of Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Finally, Truist Financial lifted their target price on shares of Vericel from $61.00 to $67.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Vericel currently has a consensus rating of “Moderate Buy” and a consensus target price of $62.14.

Insider Buying and Selling at Vericel

In other Vericel news, insider Jonathan Mark Hopper sold 10,000 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $58.72, for a total value of $587,200.00. Following the transaction, the insider now owns 58,371 shares of the company’s stock, valued at $3,427,545.12. This represents a 14.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Paul K. Wotton sold 2,600 shares of Vericel stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $58.72, for a total value of $152,672.00. Following the sale, the director now owns 27,402 shares of the company’s stock, valued at approximately $1,609,045.44. This trade represents a 8.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 15,100 shares of company stock worth $889,872 over the last quarter. Insiders own 5.20% of the company’s stock.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.